How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,040 results for

Intravenous Drug Abuse

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Effect of Dexmedetomidine for Postoperative Intravenous Patient Controlled Analgesia

Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Control Group Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h. Drug: Dezocine Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery. Drug: Flubiprofen Flubiprofen 0.5mg/kg (...) /h intravenous administration during the first two days after surgery. Experimental: Dexmedetomidine Group Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h,dexmedetomidine 0.1μg/kg/h. Drug: Dezocine Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery. Drug: Flubiprofen Flubiprofen 0.5mg/kg/h intravenous administration during the first two

2017 Clinical Trials

122. Longterm Postoperative Analgesia, Intravenous Lidocaine Infusion

: Treatment Official Title: Effect of Intravenous Lidocaine Infusion on Long Term Postoperative Pain After Spinal Fusion Surgery Actual Study Start Date : April 2015 Actual Primary Completion Date : August 2016 Actual Study Completion Date : December 2016 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Lidocaine group Patients will receive lidocaine infusion. Drug: Lidocaine patients (n = 20) will receive (...) Longterm Postoperative Analgesia, Intravenous Lidocaine Infusion Longterm Postoperative Analgesia, Intravenous Lidocaine Infusion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Longterm Postoperative

2017 Clinical Trials

123. Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

is <90 microg/mL, the subject will move to the next lowest dose. Drug: Vedolizumab IV Vedolizumab intravenous infusion Other Names: Entyvio MLN0002 Outcome Measures Go to Primary Outcome Measures : Proportion of Subjects Achieving Mucosal Healing [ Time Frame: Week 30 ] Mucosal healing is defined as Mayo endoscopic subscore less than or equal to (less than or equal to [<=] 1) point. Mayo score is used in clinical trials to assess UC disease activity. It consists of 4 disease activity variables (stool (...) , or neurodegenerative disease. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist during Screening or prior to the administration of the first dose of study drug on Day 1. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening Visit. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff

2017 Clinical Trials

124. Intravenous Dexmedetomidine for Cesarean Section

: Parturients undergoing elective caesarean delivery under epidural anaesthesia ASA I and II parturients aged 18-42 years, with singleton gestation. Parturients with verbal and written mandarin Parturients who want to use PCA intravenous analgesia and can use the pump correctly written informed consent. Exclusion Criteria Multiple gestation. A history of allergy to dexmedetomidine or other study drugs Cardiovascular disease (basic HR<50bpm or SBP<100mmHg) Opioid drugs abuse. BMI more than 35 kg/m2 (...) min and receive 1mg butorphanol after delivery. Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min. Drug: Normal Saline Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section. Experimental: Dexmedetomidine 0.03ug/kg/h group This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min

2017 Clinical Trials

125. Predictors of Response in Emergency Department Patients Receiving Intravenous Opioids for Severe Pain. (PubMed)

and strength of the correlation of initial dose and change in pain score from arrival to pre-administration. A retrospective chart review was performed in patients who received IV hydromorphone or morphine in the ED for severe pain. Key evaluated patient characteristics included patient demographics, recent opioid use, history of drug or alcohol abuse, and pain location, among others. Key evaluated environmental characteristics included initial opioid administered, time to first dose, initial pain score (...) Predictors of Response in Emergency Department Patients Receiving Intravenous Opioids for Severe Pain. The primary objective of this study was to identify significant environmental and patient characteristics of emergency department (ED) patients who responded to intravenous (IV) hydromorphone and IV morphine for severe pain. Secondary objectives were to investigate the individual effect of the significant environmental and patient characteristics of responders, and to assess the nature

2017 Pharmacotherapy

126. Renal Protection of Intravenous Dexmedetomidine During Radical Cystectomy

.Prospective human studies establishing a renal protective effect of dexmedetomidine are still questionable. Condition or disease Intervention/treatment Phase Radical Cystectomy Drug: Dexmedetomidine Drug: Fentanyl Not Applicable Detailed Description: The aim of this study is to test the hypothesis that intra-operative intravenous dexmedetomidine infusion could improve early renal function after open radical cystectomy. This randomized comparative study will be carried out on 100 patients of either sex (...) , ASA I and II with baseline serum creatinine below 1.4 mg/dl who will be submitted for radical cystectomy. The patients will be randomly allocated into two groups according to the drug infused intra-operatively; dexmedetomidine group and fentanyl group. Dexmedetomidine group: will receive loading dose (0.8μg/kg) over 20 minutes, followed by intravenous infusion (0.4μg/kg/h) and fentanyl group: will receive loading dose (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative

2017 Clinical Trials

127. A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers

or mineral supplement 24 hours prior to dosing, or anticipated use of any vitamin or mineral supplement throughout the duration of the study; Positive HIV, Hepatitis B or Hepatitis C Known history of substance abuse, drug addiction, or alcoholism within 3 years prior to Baseline; Anticipated inability to abstain from alcohol, tobacco, or caffeine use from 48 hours prior to the administration of study drug and throughout the duration of the study; History of smoking or any use of a tobacco product within (...) A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2017 Clinical Trials

128. Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and Graded Intravenous Infusion

respiratory disease; Hormonal disorders; Infection; History of drug addiction and/or alcohol abuse; Internal malignancy; Pregnancy; Suspected or confirmed poor compliance; Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03223129 Sponsors and Collaborators (...) Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and Graded Intravenous Infusion Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and Graded Intravenous Infusion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100

2017 Clinical Trials

129. Intravenous Ketamine Plus Neurocognitive Training for Depression

Depression Drug: Intravenous ketamine Behavioral: Computer-based Cognitive Training Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 150 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive (...) Neurocognition Actual Study Start Date : December 1, 2017 Estimated Primary Completion Date : October 2022 Estimated Study Completion Date : October 2023 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Ketamine + Cognitive Training Drug: Intravenous ketamine Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from

2017 Clinical Trials

130. A Multiple-Dose Study of Intravenous BNZ132‑1-40 in Healthy Adult Subjects

-blind, placebo-controlled Primary Purpose: Treatment Official Title: A Multiple-Dose Study of Intravenous BNZ132‑1-40 in Healthy Adult Subjects Actual Study Start Date : October 30, 2017 Actual Primary Completion Date : February 15, 2018 Actual Study Completion Date : March 8, 2018 Arms and Interventions Go to Arm Intervention/treatment Placebo Comparator: Placebo Normal saline Drug: Placebo Normal Saline Experimental: BNZ132-1-40 PEGylated BNZ-1 for Injection Drug: BNZ132-1-40 Injectable peptide (...) major episode of infection that required hospitalization or treatment with IV antibiotics within 30 days of screening or oral antibiotics within 14 days prior to screening. Subject has received other investigational products or therapy in the past 30 days prior to study drug administration. Serologic evidence of human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C. Subject has received an immunization within 14 days prior to study drug administration. History of alcohol or drug abuse

2017 Clinical Trials

131. Intranasal Sufentanil Versus Intravenous Morphine for the Management of Acute Pain

) push x 1 dose Drug: Sufentanil Intranasal for one dose (experimental) Drug: Normal saline Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline. Active Comparator: Intravenous morphine b. Treatment B: Normal saline 0.3 mL IN x 1 dose Morphine 0.1 mg/kg IV (...) push x 1 dose Drug: Normal saline Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline. Drug: Morphine intravenous push for one dose (active comparator) Outcome Measures Go to Primary Outcome Measures : Pain score [ Time Frame: 10 minutes after

2017 Clinical Trials

132. Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

treatment starts Participating in another clinical study currently or during the 3 months before study treatment starts. Live viral vaccination within the last month before study treatment starts A current life-threatening malignancy Emergency operation within 3 months before study treatment starts History of, or suspected, alcohol or drug abuse within 1 year before study treatment starts or currently on drug abuse therapy Pregnant and nursing women Contacts and Locations Go to No Contacts or Locations (...) Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2017 Clinical Trials

133. PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain

are relatively insufficient in China. Therefore, we conduct a prospective, multi-center, randomized controlled study to assess the efficacy and safety of comparing patient-controlled analgesia (PCA) versus non-PCA intravenous hydromorphone titration for severe cancer pain. Condition or disease Intervention/treatment Phase Cancer Pain Drug: Hydromorphone Device: PCA pump Phase 3 Detailed Description: The opioid dose for individual with cancer pain to provide adequate relief of pain with an acceptable degree (...) PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. PCA vs Non

2017 Clinical Trials

134. Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects

and 12 mg oral tablet Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 milligram (mg) dose of perampanel intravenous (IV) infusion (30-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods. Drug: Perampanel IV infusion Other Name: E2007 Drug (...) and D48); 168 (D8 and D50); 336 (D15 and D57); and 504 (D22 and D64) hours after dosing start ] t1/2 is the time required for the concentration of the drug to reach half of its original value. Dosing will occur on Day 1 of Treatment Period 1 and Day 43 of Treatment Period 2. Mean total clearance (CL) post intravenous (IV) infusion of perampanel [ Time Frame: predose; 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, and 12 (D1 and D43); 24 and 36 (D2 and D44); 48 (D3 and D45); 72 (D4 and D46); 120 (D6

2017 Clinical Trials

135. Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

: Cohort 1, Normal Renal Function Healthy control participants matched to participants enrolled in Cohort 4 (creatinine clearance ≥90 milliliters per minute [mL/min] estimated by the Cockcroft-Gault equation) will receive ETX2514SUL as a single dose of up to 1000 milligrams (mg) ETX2514 and 1000 mg sulbactam given by concurrent 3-hour intravenous (IV) infusion. Drug: ETX2514SUL Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion Experimental: Cohort 2, Mild (...) enrollment at the discretion of the Investigator Healthy Participants (Cohort 1) Healthy participants will be excluded from the study if they meet any of the following criteria: The participant's systolic blood pressure was outside the range of 90 to 150 millimeters per mercury (mmHg), diastolic blood pressure was outside the range of 40 to 95 mmHg or heart rate was outside the range of 45 to 100 beats per minute at Screening. Positive test for drugs of abuse and/or positive alcohol test Positive test

2017 Clinical Trials

136. Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma

., patients with prior malignancy must be disease free for 5 years), except curatively‐treated basal cell carcinoma Have a non‐pulmonary condition that limits lifespan to less than a year. Have a history of drug or alcohol abuse within the past 24 months. Be serum positive for HIV, hepatitis BsAg or Viremia hepatitis C Be currently participating (or have participated within the previous 30 days) in an investigational therapeutic or device trial. Have hypersensitivity to dimethyl sulfoxide (DMSO) Have (...) Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2017 Clinical Trials

137. Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids

in Adult Men and Women With Osteopenia Secondary to Glucocorticoids Actual Study Start Date : October 14, 2016 Estimated Primary Completion Date : January 2020 Estimated Study Completion Date : June 2020 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: LLP2A-ALENDRONATE 50, 150, 400 or 750 μg/kg or placebo given as a one time intravenous administration over 120 minutes. Drug: LLP2A (...) -ALENDRONATE A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes. Other Name: LLP2A-Ale Placebo Comparator: Placebo placebo given as a one time intravenous administration over 120 minutes. Drug: Placebo Placebo, one time single administration given intravenously over 120 minutes. Outcome Measures Go to Primary

2017 Clinical Trials

138. A Comparison of Dexmedetomidine Versus Propofol for Use in Intravenous Sedation

in Intravenous Sedation Actual Study Start Date : March 20, 2018 Estimated Primary Completion Date : April 1, 2019 Estimated Study Completion Date : April 1, 2019 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Propofol Group Group of patients to be administered a standard Propofol, Midazolam, Fentanyl anesthesia combination. Drug: Propofol, Midazolam, and Fentanyl Administration of Propofol, Midazolam (...) ASA Class I or II English-speaking and Spanish-speaking subjects Exclusion Criteria: ASA Class III or higher Patients taking alpha-2 agonists or benzodiazepines Allergy or drug reaction to any of the drugs used in this study (benzodiazepines, opioids, propofol, alpha-2 agonists, NSAIDs, local anesthetic) BMI greater than 30 History of or current substance abuse or alcoholism History of mood-altering medications, tranquilizers, or antidepressants. Pregnant females Contacts and Locations Go

2017 Clinical Trials

139. An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2017 Clinical Trials

140. Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)

to evaluate pharmacokinetics and dosimetry of intravenously injected Tc 99m tilmanocept at three mass doses (50 µg, 200 µg, and 400 µg) radiolabeled with 10 millicuries (mCi) Tc 99m. Condition or disease Intervention/treatment Phase Arthritis, Rheumatoid Drug: Tilmanocept Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 0 participants Allocation: Non-Randomized Intervention Model: Sequential Assignment Masking: None (Open Label (...) for: Arms and Interventions Go to Arm Intervention/treatment Experimental: 50 ug Tilmanocept Single dose of 50 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m Drug: Tilmanocept Intravenously administered Technetium Tc 99m tilmanocept Experimental: 200 ug Tilmanocept Single dose of 200 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m Drug: Tilmanocept Intravenously administered Technetium Tc 99m tilmanocept Experimental: 400 ug Tilmanocept Single dose of 400 ug tilmanocept radiolabeled

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>